( April 2, 2026, 1:09 PM EDT) -- PHOENIX — A biomaterials scientist retained by the plaintiffs in the multidistrict litigation involving C.R. Bard Inc.’s implanted port catheter (IPC) device can largely offer her opinions on design defects but cannot opine that a certain defect led to a risk of infection, the judge overseeing the MDL said after finding that the scientist’s testimony meets the requirements of Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals Inc....